A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
David C KlonoffMark L EvansWendy LaneHans-Peter KempePr Eric RenardJ Hans DeVriesTina GraungaardAgon HyseniTheis GondolfTadej BattelinoPublished in: Diabetes, obesity & metabolism (2019)
Faster aspart provides an effective and safe option for CSII treatment in T1D.